Highlights & Basics
- Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies.
- Clinical history and presenting signs/symptoms depend on the type and location of lymphoma, and disease stage at presentation.
- Diagnosis is confirmed by histopathology (e.g., biopsy of lymph node or extranodal sites) and immunophenotyping.
- Diffuse large B-cell lymphoma is the most common type of NHL.
- Treatment varies depending on the histologic subtype, location of lymphoma, and disease stage; symptom severity informs decisions about when to start therapy.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication].[Full Text]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: T-cell lymphomas [internet publication].[Full Text]
National Comprehensive Cancer Network. NCCN central nervous system cancers [internet publication].[Full Text]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas [internet publication].[Full Text]
Eyre TA, Cwynarski K, d'Amore F, et al. Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Nov;36(11):1263-84.[Abstract][Full Text]
1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.[Abstract][Full Text]
2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-53.[Abstract][Full Text]
3. Hingorjo MR, Syed S. Presentation, staging and diagnosis of lymphoma: a clinical perspective. J Ayub Med Coll Abbottabad. 2008 Oct-Dec;20(4):100-3.[Abstract]
4. Wang G, Chang Y, Wu X, et al. Clinical features and prognostic factors of primary bone marrow lymphoma. Cancer Manag Res. 2019;11:2553-63.[Abstract][Full Text]
5. Yu Y, Dong X, Tu M, et al. Primary mediastinal large B cell lymphoma. Thorac Cancer. 2021 Nov;12(21):2831-7.[Abstract][Full Text]
6. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004 Oct;15(10):1467-75.[Abstract][Full Text]
7. Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J. 2002 Sep;20(3):750-62.[Abstract][Full Text]
8. Kaji D, Ota Y, Sato Y, et al. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv. 2020 Sep 22;4(18):4442-50.[Abstract][Full Text]
9. Khdhir M, El Annan T, El Amine MA, et al. Complications of lymphoma in the abdomen and pelvis: clinical and imaging review. Abdom Radiol (NY). 2022 Aug;47(8):2937-55.[Abstract][Full Text]
10. Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022 Sep 1;140(9):971-9.[Abstract][Full Text]
11. Müller A, Dreyling M, Roeder F, et al. Primary bone lymphoma: clinical presentation and therapeutic considerations. J Bone Oncol. 2020 Dec;25:100326.[Abstract][Full Text]
12. Monnard V, Sun A, Epelbaum R, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):817-23.[Abstract]
13. Jaffe ES, Ashar BS, Clemens MW, et al. Best practices guideline for the pathologic diagnosis of breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2020 Apr 1;38(10):1102-11.[Abstract][Full Text]
14. Opyrchal M, Figanbaum T, Ghosh A, et al. Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. Case Rep Med. 2010;2010:610969.[Abstract][Full Text]
15. Belay Y, Yirdaw K, Enawgaw B. Tumor lysis syndrome in patients with hematological malignancies. J Oncol. 2017;2017:9684909.[Abstract][Full Text]
16. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: non-Hodgkin lymphoma. 2025 [internet publication].[Full Text]
17. Cancer Research UK. Non-Hodgkin lymphoma incidence statistics. Oct 2024 [internet publication].[Full Text]
18. Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sep 1;26(25):4124-30.[Abstract][Full Text]
19. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel). 2021 Jan 30;9(1):5.[Abstract][Full Text]
20. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443-59.[Abstract][Full Text]
21. Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 2017 Dec 1;152(12):1161-8.[Abstract]
22. US Food and Drug Administration. Medical device reports of breast implant-associated anaplastic large cell lymphoma. Jun 2025 [internet publication].[Full Text]
23. American Society of Plastic Surgeons. BIA-ALCL physician resources. May 2025 [internet publication].[Full Text]
24. Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020 May;73(5):841-6.[Abstract][Full Text]
25. Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2022 Feb 17;139(7):995-1012.[Abstract][Full Text]
26. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013 Aug 21;105(16):1221-9.[Abstract]
27. Tao J, Luo Q, Haas CB, et al. Risk of lymphomas among people with HIV in the United States during 2001-2019. J Natl Cancer Inst. 26 Aug 2025 [Epub ahead of print].[Abstract]
28. Ramaswami R, Chia G, Dalla Pria A, et al. Evolution of HIV-associated lymphoma over 3 decades. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):177-83.[Abstract]
29. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004 Feb 1;10(3):803-21.[Abstract][Full Text]
30. Donzel M, Bonjour M, Combes JD, et al. Lymphomas associated with Epstein-Barr virus infection in 2020: results from a large, unselected case series in France. EClinicalMedicine. 2022 Dec;54:101674.[Abstract][Full Text]
31. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002 Jul 11;347(2):89-94.[Abstract][Full Text]
32. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8.[Abstract][Full Text]
33. Alkrekshi A, Kassem A, Park C, et al. Risk of non-Hodgkin's lymphoma in HCV patients in the United States between 2013 and 2020: a population-based study. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e832-8.[Abstract][Full Text]
34. Mehta-Shah N, Ratner L, Horwitz SM. Adult T-cell leukemia/lymphoma. J Oncol Pract. 2017 Aug;13(8):487-92.[Abstract][Full Text]
35. Cesarman E, Chadburn A, Rubinstein PG. KSHV/HHV8-mediated hematologic diseases. Blood. 2022 Feb 17;139(7):1013-25.[Abstract][Full Text]
36. Melenotte C, Million M, Audoly G, et al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood. 2016 Jan 7;127(1):113-21.[Abstract]
37. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;165(20):2337-44.[Abstract][Full Text]
38. Ekström Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008 Apr 15;111(8):4029-38.[Abstract][Full Text]
39. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006 Jan 4;98(1):51-60.[Abstract]
40. Riaz IB, Faridi W, Patnaik MM, et al. A systematic review on predisposition to lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity). Front Immunol. 2019;10:777.[Abstract][Full Text]
41. Yamak B, Hicsonmez G, Ozsoylu S, et al. An infant with Chediak-Higashi syndrome and lymphoma. Clin Pediatr (Phila). 1972 May;11(5):277-80.[Abstract]
42. Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005 Aug 17;97(16):1204-10.[Abstract]
43. Ji J, Zöller B, Sundquist J, et al. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int J Cancer. 2016 Aug 15;139(4):754-8.[Abstract]
44. Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014 Apr 23;11(4):4449-527.[Abstract][Full Text]
45. De Roos AJ, Fritschi L, Ward MH, et al. Herbicide use in farming and other jobs in relation to non-Hodgkin's lymphoma (NHL) risk. Occup Environ Med. 2022 Dec;79(12):795-806.[Abstract][Full Text]
46. Kachuri L, Beane Freeman LE, Spinelli JJ, et al. Insecticide use and risk of non-Hodgkin lymphoma subtypes: a subset meta-analysis of the North American Pooled Project. Int J Cancer. 2020 Dec 15;147(12):3370-83.[Abstract][Full Text]
47. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010 Feb;69(2):400-8.[Abstract]
48. Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk. Plast Reconstr Surg. 2017 Oct;140(4):645-54.[Abstract]
49. Doren EL, Miranda RN, Selber JC, et al. US epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017 May;139(5):1042-50.[Abstract]
50. de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018 Mar 1;4(3):335-41.[Abstract][Full Text]
51. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol. 2013 Apr;131(4):959-71.[Abstract][Full Text]
52. Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565-610.[Abstract]
53. Grau M, López C, Martín-Subero JI, Beà S. Cytogenomics of B-cell non-Hodgkin lymphomas: the "old" meets the "new". Best Pract Res Clin Haematol. 2023 Dec;36(4):101513.[Abstract][Full Text]
54. Seifert M, Scholtysik R, Küppers R. Origin and pathogenesis of B cell lymphomas. Methods Mol Biol. 2013;971:1-25.[Abstract]
55. Shingleton J, Wang J, Baloh C, et al. Non-hodgkin lymphomas: malignancies arising from mature B cells. Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):a034843.[Abstract][Full Text]
56. Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018 May 24;131(21):2320-30.[Abstract][Full Text]
57. Clayberger C, Krensky AM. T-cell and NK-cell immunity. In: Hoffman R, Benz EJ, Shattil SJ, eds. Hematology: basic principles and practice. 4th ed. Oxford, UK: Churchill Livingstone; 2005:135-47.
58. Ito Y, Kogure Y, Kataoka K. Biological and clinical relevance of genetic alterations in peripheral T-cell lymphomas. JMA J. 2025 Apr 28;8(2):345-53.[Abstract][Full Text]
59. Scoville SD, Freud AG, Caligiuri MA. Modeling human natural killer cell development in the era of innate lymphoid cells. Front Immunol. 2017;8:360.[Abstract][Full Text]
60. Somasundaram N, Lim JQ, Ong CK, et al. Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). J Hematol Oncol. 2019 Mar 15;12(1):28.[Abstract][Full Text]
61. Qi S, Cai Q. Advancing understanding of mature T-cell and natural killer-cell lymphomas. Lancet Haematol. 2025 Oct;12(10):e770-1.[Abstract]
62. Rajagopal A, Thompson CA, Chorzempa AK, et al. Advanced enteropathy-associated T cell lymphoma (EATL) presenting with severe malabsorption and concomitantly diagnosed coeliac disease (CD). BMJ Case Rep. 2023 Dec 23;16(12):e258265.[Abstract]
63. Santacroce G, Vanoli A, Aronico N, et al. Different survival outcomes of small bowel adenocarcinomas and T-cell lymphomas associated with celiac disease. Am J Gastroenterol. 5 Jun 2025 [Epub ahead of print].[Abstract]
64. Franca RA, Travaglino A, Varricchio S, et al. HIV prevalence in primary central nervous system lymphoma: asystematic review and meta-analysis. Pathol Res Pract. 2020 Nov;216(11):153192.[Abstract][Full Text]
65. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009 Feb 5;113(6):1213-24.[Abstract][Full Text]
66. Clerico M, Dogliotti I, Aroldi A, et al. Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options. J Clin Med. 2022 Dec 19;11(24):7542.[Abstract][Full Text]
67. Zhou JC, Wu MQ, Peng ZM, et al. Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study. Medicine (Baltimore). 2020 Feb;99(7):e19015.[Abstract][Full Text]
68. Piquer Gibert M, Alsina L, Giner Muñoz MT, et al. Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency. Eur J Pediatr. 2015 Aug;174(8):1069-76.[Abstract]
69. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas [internet publication].[Full Text]
70. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: T-cell lymphomas [internet publication].[Full Text]
71. Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003 Apr 1;101(7):2464-72.[Abstract][Full Text]
72. Vitiello P, Sica A, Ronchi A, et al. Primary cutaneous B-cell lymphomas: an update. Front Oncol. 2020;10:651.[Abstract][Full Text]
73. Forkasiewicz A, Dorociak M, Stach K, et al. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25:35.[Abstract][Full Text]
74. Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: a British Society for Haematology Guideline. Br J Haematol. 2024 Apr;204(4):1178-92.[Abstract][Full Text]
75. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38.[Abstract]
76. Kroft SH, Sever CE, Bagg A, et al. Laboratory workup of lymphoma in adults: guideline from the American Society for Clinical Pathology and the College of American Pathologists. Arch Pathol Lab Med. 2021 Mar 1;145(3):269-90.[Abstract][Full Text]
77. Turton P, El-Sharkawi D, Lyburn I, et al. UK guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group. Br J Haematol. 2021 Feb;192(3):444-58.[Abstract][Full Text]
78. National Comprehensive Cancer Network. NCCN central nervous system cancers [internet publication].[Full Text]
79. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas [internet publication].[Full Text]
80. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.[Abstract][Full Text]
81. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology. 2004 Sep;232(3):823-9.[Abstract]
82. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58.[Abstract][Full Text]
83. Papajik T, Myslivecek M, Skopalova M, et al. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT. Neoplasma. 2011;58(4):291-7.[Abstract][Full Text]
84. Broccoli A, Nanni C, Cappelli A, et al. Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3058-65.[Abstract][Full Text]
85. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008 Mar;93(3):471-2.[Abstract][Full Text]
86. Noy A, Schöder H, Gönen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009 Mar;20(3):508-12.[Abstract][Full Text]
87. Rajamäki A, Kuitunen H, Sorigue M, et al. FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma. Cancer Med. 2023 Jan;12(1):407-11.[Abstract][Full Text]
88. Burggraaff CN, de Jong A, Hoekstra OS, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):65-79.[Abstract][Full Text]
89. Seifert R, Kersting D, Rischpler C, et al. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial. Leukemia. 2022 Dec;36(12):2845-52.[Abstract][Full Text]
90. Dührsen U, Müller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018 Jul 10;36(20):2024-34.[Abstract][Full Text]
91. Schmitz C, Rekowski J, Müller SP, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: a subgroup analysis of the PETAL trial. Hematol Oncol. 2020 Aug;38(3):244-56.[Abstract][Full Text]
92. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009 Apr 10;27(11):1906-14.[Abstract]
93. Ali FS, Nguyen MH, Hernaez R, et al. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology. 2025 Feb;168(2):267-84.[Abstract]
94. Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024 Jan;204(1):86-107.[Abstract][Full Text]
95. Boyle MJ, Swanson CE, Turner JJ, et al. Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. Br J Haematol. 1990 Dec;76(4):506-12.[Abstract]
96. Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkitt lymphoma. Lancet Haematol. 2020 Aug;7(8):e594-e600.[Abstract]
97. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555-62.[Abstract][Full Text]
98. Emile JF, Azoulay D, Gornet JM, et al. Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. Ann Oncol. 2001 Jul;12(7):1005-10.[Abstract][Full Text]
99. Boddana PV, Tomson CR, Austen B, et al. A case of lymphoma presenting as splenic infarction. BMJ Case Rep. 20 Apr 2009 [Epub ahead of print].[Abstract][Full Text]
100. Weidenbaum C, Kushwah A, Geromes A, et al. Primary mediastinal B-cell lymphoma presenting as chest pain in a young woman and treated with EPOCH-R. J Community Hosp Intern Med Perspect. 2022;12(5):54-6.[Abstract][Full Text]
101. Rowbotham D, Wendon J, Williams R. Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut. 1998 Apr;42(4):576-80.[Abstract][Full Text]
102. Zhao D, Wei L, Li L, et al. Atypical presentation of secondary hepatic lymphoma with severe hepatic involvement: a case report and literature review. Medicine (Baltimore). 2025 Jul 18;104(29):e43411.[Abstract][Full Text]
103. Chaudhari D, Khan S, Saleem A, et al. Obstructive jaundice as an initial manifestation of non-hodgkin lymphoma: treatment dilemma and high mortality. Case Rep Med. 2013;2013:259642.[Abstract][Full Text]
104. Silveira LHJ, de Oliveira VS, Pinheiro RF. Breast implant-associated - anaplastic large cell lymphoma: a call for disease awareness. Hematol Transfus Cell Ther. 2023 Jan-Mar;45(1):124-6.[Abstract][Full Text]
105. Fracol ME, Rodriguez MM, Clemens MW. A spectrum of disease: breast implant-associated anaplastic large cell lymphoma, atypicals, and other implant associations. Clin Plast Surg. 2023 Apr;50(2):249-57.[Abstract][Full Text]
106. Tevis SE, Hunt KK, Miranda RN, et al. Breast implant-associated anaplastic large cell lymphoma: a prospective series of 52 patients. Ann Surg. 2022 Jan 1;275(1):e245-9.[Abstract][Full Text]
107. Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: a British Society of Haematology Guideline. Br J Haematol. 2024 Jan;204(1):86-107.[Abstract][Full Text]
108. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4.[Abstract]
109. Arendt K, Demaerschalk BM, Wingerchuk DM, et al. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20.[Abstract]
110. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204.[Abstract]
111. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.[Abstract][Full Text]
112. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.[Abstract][Full Text]
113. Fraga M, Forteza J. Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features. Histol Histopathol. 2007 Aug;22(8):923-35.[Abstract]
114. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630-6.[Abstract]
115. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993 Sep 30;329(14):987-94.[Abstract][Full Text]
116. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 2;339(1):21-6.[Abstract][Full Text]
117. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42.[Abstract][Full Text]
118. Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998 Jul;16(7):2332-8.[Abstract]
119. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65.[Abstract][Full Text]
120. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016 Sep 10;34(26):3150-6.[Abstract]
121. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65.[Abstract][Full Text]
122. Arcaini L, Bommier C, Alderuccio JP, et al. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024 Jun;72:102592.[Abstract][Full Text]
123. Olszewski AJ, Jakobsen LH, Collins GP, et al. Burkitt llymphoma International Prognostic Index. J Clin Oncol. 2021 Apr 1;39(10):1129-38.[Abstract][Full Text]
124. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pediatric aggressive mature B-cell lymphomas [internet publication].[Full Text]
125. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma [internet publication].[Full Text]
126. Eyre TA, Cwynarski K, d'Amore F, et al. Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Nov;36(11):1263-84.[Abstract][Full Text]
127. d'Amore F, Federico M, de Leval L, et al. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jun;36(6):626-44.[Abstract][Full Text]
128. Hübel K, Bower M, Aurer I, et al. Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Oct;35(10):840-59.[Abstract][Full Text]
129. Ferreri AJM, Illerhaus G, Doorduijn JK, et al. Primary central nervous system lymphomas: EHA-ESMO clinical practice guideline for diagnosis, treatment and follow-up. Hemasphere. 2024 Jun;8(6):e89.[Abstract][Full Text]
130. Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(suppl 4):iv30-40.[Abstract][Full Text]
131. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. May 2025 [internet publication].[Full Text]
132. Chaganti S, Fox CP, Maybury BD, et al. Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2025 Jun;206(6):1593-603.[Abstract][Full Text]
133. Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: a British Society for Haematology Guideline. Br J Haematol. 2024 Jan;204(1):108-26.[Abstract][Full Text]
134. Cwynarski K, Cummin T, Osborne W, et al. Management of secondary central nervous system lymphoma. Br J Haematol. 2023 Jan;200(2):160-9.[Abstract][Full Text]
135. Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022 Feb;196(3):507-22.[Abstract][Full Text]
136. British Society for Haematology. Guideline on the investigation and management of follicular lymphoma. June 2020 [internet publication].[Full Text]
137. Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019 Feb;184(3):348-63.[Abstract][Full Text]
138. National Institute for Health and Care and Excellence. Non-Hodgkin's lymphoma: diagnosis and management. July 2016 [internet publication].[Full Text]
139. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007 Jul 1;110(1):29-36.[Abstract][Full Text]
140. Ghose A, Elias HK, Guha G, et al. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis--a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):451-7.[Abstract]
141. Eyre TA, Savage KJ, Cheah CY, et al. CNS prophylaxis for diffuse large B-cell lymphoma. Lancet Oncol. 2022 Sep;23(9):e416-e26.[Abstract]
142. Wilson MR, Cwynarski K, Eyre TA, et al. Central nervous system prophylaxis in large B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2024 Aug 11.[Abstract][Full Text]
143. Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20;139(3):413-23.[Abstract][Full Text]
144. Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022 Apr 21;139(16):2499-511.[Abstract][Full Text]
145. Sawalha Y, Maddocks K. Novel treatments in B cell non-Hodgkin's lymphomas. BMJ. 2022 Apr 20;377:e063439.[Abstract][Full Text]
146. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021 Mar 4;384(9):842-58.[Abstract]
147. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021 Dec 10;39(35):3978-92.[Abstract][Full Text]
148. Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug Ther Bull. 2025 Sep 29;63(10):148.[Abstract]
149. US Food and Drug Administration. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen Rreceptor (CAR) T cell Immunotherapies. Apr 2024 [internet publication]. [Full Text]
150. Patel NP, Doukas PG, Gordon LI, et al. Cardiovascular toxicities of CAR T-cell therapy. Curr Oncol Rep. 2021 May 3;23(7):78.[Abstract]
151. Totzeck M, Michel L, Lin Y, et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022 May 21;43(20):1928-40.[Abstract][Full Text]
152. Cook MR, Williams LS, Dorris CS, et al. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica. 2024 Mar 1;109(3):846-56.[Abstract][Full Text]
153. Morgenstern Y, Aumann S, Goldschmidt N, et al. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: results of a bi-center retrospective study. Cancer Med. 2021 Dec;10(24):8866-75.[Abstract][Full Text]
154. Citterio G, Reni M, Gatta G, et al. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017 May;113:97-110.[Abstract]
155. Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023 Jun 15;9(1):29.[Abstract][Full Text]
156. Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016 Aug;3(8):e388-97.[Abstract]
157. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 1;31(25):3061-8.[Abstract][Full Text]
158. Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021 Jul 1;7(7):993-1003.[Abstract][Full Text]
159. Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013 Nov 1;31(31):3971-9.[Abstract][Full Text]
160. Fenske TS, Wang XV, Till BG, et al.Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial. Blood, 2024;144:LBA-6.
161. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017 Oct 26;130(17):1903-10.[Abstract][Full Text]
162. Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020 Jun;105(6):1604-12.[Abstract][Full Text]
163. Howard OM, Gribben JG, Neuber DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002 Mar 1;20(5):1288-94.[Abstract]
164. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92.[Abstract]
165. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec;16(12):3803-9.[Abstract]
166. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct 20;24(30):4867-74.[Abstract]
167. Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019 Nov;33(11):2762-2766.[Abstract][Full Text]
168. Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021 Jun 22;5(12):2577-2585.[Abstract][Full Text]
169. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul;13(7):716-23.[Abstract][Full Text]
170. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-94.[Abstract][Full Text]
171. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020 Apr 2;382(14):1331-42.[Abstract][Full Text]
172. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-97.[Abstract][Full Text]
173. Alduaij W, Jiang A, Villa D, et al. CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL. Blood. 2025 Feb 6;145(6):590-6.[Abstract]
174. Epperla N, Zayac AS, Landsburg DJ, et al. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024 Oct 22;8(20):5355-64.[Abstract][Full Text]
175. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-40.[Abstract]
176. Thieblemont C, Bernard S, Molina T. Management of aggressive lymphoma in very elderly patients. Hematol Oncol. 2017 Jun;35:49-53.[Abstract][Full Text]
177. Mead M, Cederleuf H, Björklund M, et al. Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients. Blood Adv. 2022 Apr 12;6(7):2120-8.[Abstract][Full Text]
178. Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013 Mar 28;121(13):2529-32.[Abstract][Full Text]
179. d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9.[Abstract]
180. Zhai Y, Wang J, Jiang Y, et al. The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis. Expert Rev Hematol. 2022 Mar;15(3):265-72.[Abstract]
181. Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 May 1;125(9):1507-17.[Abstract][Full Text]
182. Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018 Mar 1;29(3):715-23.[Abstract][Full Text]
183. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10.[Abstract]
184. Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 Apr 20;37(12):984-91.[Abstract][Full Text]
185. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-47.[Abstract][Full Text]
186. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-44.[Abstract]
187. Cassanello G, Drill E, Qiu A, et al. Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era. Blood Cancer J. 2025 Aug 29;15(1):150.[Abstract][Full Text]
188. Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016 Jan 10;34(2):160-8.[Abstract][Full Text]
189. Longo B, Di Napoli A, Curigliano G, et al. Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL. Breast. 2022 Dec;66:332-41.[Abstract][Full Text]
190. The Plastic Surgery Foundation. PROFILE registry. [internet publication].[Full Text]
191. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003 Nov;39(16):2264-72.[Abstract]
192. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212.[Abstract]
193. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic growth factors [internet publication].[Full Text]
194. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1023-30.[Abstract]
195. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].[Full Text]
196. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 Oct;17(10):3333-55.[Abstract]
197. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.[Abstract][Full Text]
198. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16.[Abstract][Full Text]
199. Lee DH, Hawk F, Seok K, et al. Association between ibrutinib treatment and hypertension. Heart. 2022 Mar;108(6):445-50.[Abstract]
200. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019 Nov 28;134(22):1919-28.[Abstract][Full Text]
201. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 6;126(6):739-45.[Abstract][Full Text]
202. Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of Bruton tyrosine kinase inhibitors. Br J Haematol. 2022 Jan;196(1):70-8.[Abstract][Full Text]
203. Boulanger E, Gérard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005 Jul 1;23(19):4372-80.[Abstract][Full Text]
204. Kim TM, Taszner M, Novelli S, et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024 Nov;35(11):1039-47.[Abstract][Full Text]
205. Kim WS, Kim TM, Cho SG, et al. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-39.[Abstract][Full Text]
206. Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016 Apr 1;34(10):1104-11.[Abstract][Full Text]
207. Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016 Mar 17;127(11):1410-6.[Abstract][Full Text]
208. Viardot A, Hess G, Bargou RC, et al. Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2020 Nov;61(11):2767-70.[Abstract][Full Text]
209. Coyle L, Morley NJ, Rambaldi A, et al. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020 Sep;61(9):2103-12.[Abstract][Full Text]
210. Katz DA, Morris JD, Chu MP, et al. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Leuk Lymphoma. 2022 Sep;63(9):2063-73.[Abstract][Full Text]
211. Ghobadi A, Foley NC, Cohen J, et al. Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Adv. 2024 Feb 13;8(3):513-22.[Abstract][Full Text]
212. Ji J, Liu Z, Kuang P, et al. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas. Int J Cancer. 2021 Dec 15;149(12):2075-82.[Abstract][Full Text]
213. ClinicalTrials.gov. APG-1252 monotherapy or in combination with other therapeutic agent in subjects with relapsed or refractory non-Hodgkin lymphoma. Jan 2024 [internet publication].[Full Text]
214. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation (HCT) [internet publiction].[Full Text]
215. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.[Abstract][Full Text]
216. Couderc B, Dujols JP, Mokhtari F, et al. The management of adult aggressive non-Hodgkin's lymphomas. Crit Rev Oncol Hematol. 2000 Jul;35(1):33-48.[Abstract]
217. Smith SM, Salles G. Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. Haematologica. 2022 Jan 1;107(1):4-6.[Abstract][Full Text]
218. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: NHL - diffuse large B-cell lymphoma (DLBCL) [internet publication].[Full Text]
219. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: NHL - follicular lymphoma [internet publication].[Full Text]
220. Ferreri AJ, Abrey LE, Blay J-Y, et al. Management of primary central nervous system lymphoma: a summary statement from the 8th International Conference on Malignant Lymphoma. J Clin Oncol. 2003 Jun 15;21(12):2407-14.[Abstract]
221. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003 Nov 1;21(21):3948-54.[Abstract]
222. Mburu W, Devesa SS, Check D, et al. Incidence of Burkitt lymphoma in the United States during 2000 to 2019. Int J Cancer. 2023 Sep 15;153(6):1182-91.[Abstract][Full Text]
223. Arora R, Lefante J, Saba NS. Updated trends in incidence and survival of mantle cell lymphoma from 2000 to 2020. Blood. 2023;142:5160.[Full Text]
224. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 Aug 28;124(9):1473-80.[Abstract][Full Text]
225. Ali H, Bajwa S, Narra SA, et al. ALK-positive anaplastic large cell lymphoma: statistics and survival trends. J Clin Oncol. 2025;43:7078.[Full Text]
226. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10;32(2):114-20.[Abstract][Full Text]
227. Ferrufino-Schmidt MC, Medeiros LJ, Liu H, et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol. 2018 Mar;42(3):293-305.[Abstract][Full Text]
228. Li J, Wu Z, Zhao N. Individual patient data meta-analysis from 16 trials for safety factors in cytokine release syndrome after CAR-T therapy in patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia. Adv Ther. 2019 Oct;36(10):2881-94.[Abstract]
